In part 5, Prof. Caplan discusses: Mesenchymal stem cells produce huge quantities of bio-molecules, some of which are immunosuppressive; MSCs put up a curtain of molecules around themselves that allows donor (allogeneic) MSCs to be transplanted into a recipient free from immune response; The bio-chemical mechanism of how MSCs shield themselves from host T Cells; Allogeneic hematopoietic stem cell business model; Treatment of graft vs. host disease in children and adults; Treatment of Crohn’s disease with allogeneic mesenchymal stem cells.
June 19, 2013 by
VIDEO – The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (Part 5)
June 11, 2013 by
The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (VIDEO Part 3)
In part 3, Professor Caplan discusses the science behind mesenchymal stem cells: sources of mesenchymal stem cells (MSCs), because all MSCs are pericytes one can find them in any tissue that has blood vessels, pericytes express markers of MSCs, frequency of pericytes in human tissue, most abundant source of pericytes is adipose (fat) tissue, adipose-derived stem cells, how MSCs are separated from fat, chemistries MSCs from different tissues are not the same, MSCs function at sites of injury, mesenchymal stem cell homing in mice, MSCs don’t make fat, they don’t make muscle. They come back as pericytes, and not all pericytes are MSCs.
June 10, 2013 by
The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (VIDEO Part 2)
In Part 2, Prof. Caplan discusses the two types of regenerative medicine: tissue engineering and in vivo tissue regeneration, hematapoietic and mesenchymal stem cells. All mesenchymal stem cells are pericytes and have immuno-modulatory and trophic properties
Prof. Caplan was speaking in Panama City, Panama at “La Medicina Del Futuro En El Presente”, an event organized by the honarable Ruben Berrocal MD, Minister of Science, Technology and Innovation SENACYT (National Secretariat of Science, Technology and Innovation) and Prof. K. S. Jagannatha Rao, Ph.D., FNASc, FABAP, FASB, FLS (Reino Unido) Director INDICASAT-AIP (Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia — Institute for Scientific Research and High Technology Services).
June 6, 2013 by
The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (VIDEO Part 1)
Professor Arnold Caplan of Case Western Reserve University is widely regarded as “The Father of the Mesenchymal Stem Cell”. This lecture is a “must see” for anyone interested in stem cell therapy. In Part 1, Prof. Caplan proposes a new regulatory pathway for approval of cell-based therapies and regenerative medicine called “Progressive Approval” to replace the current US FDA system that is now in place.
Prof. Caplan was speaking in Panama City, Panama at “La Medicina Del Futuro En El Presente”, an event organized by the honarable Ruben Berrocal MD, Minister of Science, Technology and Innovation SENACYT (National Secretariat of Science, Technology and Innovation) and Prof. K. S. Jagannatha Rao, Ph.D., FNASc, FABAP, FASB, FLS (Reino Unido) Director INDICASAT-AIP (Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia — Institute for Scientific Research and High Technology Services).
June 6, 2013 by
Arnold Caplan and Riccardo Calafiore inside Medistem Panama stem cell laboratory
Arnold Caplan PhD and Riccardo Calafiore
Prof. Arnold Caplan of Case Western Reserve University and Prof. Riccardo Calafiore of the University of Perugia, Italy inside our stem cell lab. Prof. Caplan and Prof. Calafiore toured one of our three clean rooms and viewed stem cells during their visit.
They were speaking in Panama City, Panama at “La Medicina Del Futuro En El Presente”, an event organized by the honarable Ruben Berrocal MD, Minister of Science, Technology and Innovation SENACYT (National Secretariat of Science, Technology and Innovation) and Prof. K. S. Jagannatha Rao, Ph.D., FNASc, FABAP, FASB, FLS (Reino Unido) Director INDICASAT-AIP (Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia – Institute for Scientific Research and High Technology Services).
May 20, 2013 by
Arnold Caplan PhD of Case Western Reserve University and Riccardo Calafiore of Perugia University in Italy tour Medistem stem cell lab in Panama
Arnold Caplan PhD, Neil Riordan PhD and Riccardo Calafiore MD at Medistem Labs Panama
Professor Arnold Caplan (left) and Professor Riccardo Calafiore (right) pose with Medistem Labs Panama Founder, Neil Riordan, PhD. Dr. Riordan is also the Founder of Stem Cell Institute in Panama City, Panama.
Prof. Caplan and Prof. Calafiore were in Panama City with Amit Patel MD to speak at “La Medicina Del Futuro En El Presente”, an event organized by the honarable Ruben Berrocal MD, Minister of Science, Technology and Innovation SENACYT (National Secretariat of Science, Technology and Innovation) and Prof. K. S. Jagannatha Rao, Ph.D., FNASc, FABAP, FASB, FLS (Reino Unido) Director INDICASAT-AIP (Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia – Institute for Scientific Research and High Technology Services).
Prof. Caplan is a Professor of Biology and General Medical Sciences (oncology) at Case Western Reserve University and the Director of the Skeletal Research Center at Case Western Reserve. Prof. Caplan is widely regarded as “The father of the mesenchymal stem cell”.
Prof. Calafiore is the Head of the Division of Endocrinology and Metabolism at the Medical School at the University of Perugia, Italy and Director of the Interdisciplinary Laboratory for Endocrine and Organ Transplant at the University of Perugia School of Medicine. He is also a director at ALTuCELL.
Amit Patel, MD, MS, is an associate professor in the Division of Cardiothoracic Surgery at the University of Utah School of Medicine and Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah
Neil Riordan PhD is Founder of Stem Cell Institute in Panama City, Panama and the President of Medistem Panama. He is also CEO of Aidan Products.
April 30, 2013 by
The dual effect of MSCs on tumour growth and tumour angiogenesis
Michelle Kéramidas, Florence de Fraipont, Anastassia Karageorgis, Anaïck Moisan, Virginie Persoons, Marie-Jeanne Richard, Jean-Luc Coll and Claire Rome
Abstract (provisional)
Introduction
Understanding the multiple biological functions played by human mesenchymal stem cells (hMSCs) as well as their development as therapeutics in regenerative medicine or in cancer treatment are major fields of research. Indeed, it has been established that hMSCs play a central role in the pathogenesis and progression of tumours, but their impact on tumour growth remains controversial.
Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.
Methods
In this study, we investigated the influence of hMSCs on the growth of pre-established tumours. We engrafted nude mice with luciferase-positive mouse adenocarcinoma cells (TSA-Luc+) to obtain subcutaneous or lung tumours. When tumour presence was confirmed by non-invasive bioluminescence imaging, hMSCs were injected into the periphery of the SC tumours or delivered by systemic intravenous injection in mice bearing either SC tumours or lung metastasis.
Results
Regardless of the tumour model and mode of hMSC injection, hMSC administration was always associated with decreased tumour growth due to an inhibition of tumour cell proliferation, likely resulting from deep modifications of the tumour angiogenesis. Indeed, we established that although hMSCs can induce the formation of new blood vessels in a non-tumoural cellulose sponge model in mice, they do not modify the overall amount of haemoglobin delivered into the SC tumours or lung metastasis. We observed that these tumour vessels were reduced in number but were longer.
Conclusions
Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.
Original Link: http://stemcellres.com/content/4/2/41/abstract
